Showing results (1211-1220 of 1,538) with videos related to

Sort By:
Pageof 154
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trialsD Y C Heng, T K Choueiri, B I Rini, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|January 23, 2017
Epilepsy in patients with GRIN2A alterations: Genetics, neurodevelopment, epileptic phenotype and response to anticonvulsive drugsC von Stülpnagel, M Ensslen, R S Møller, et al.
Journal for Immunotherapy of Cancer|April 23, 2015
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study resultsAsim Amin, Arkadiusz Z Dudek, Theodore F Logan, et al.
European Urology|August 22, 2013
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapyRana R McKay, Nils Kroeger, Wanling Xie, et al.
Cancer|March 26, 2020
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA resultsSumanta K Pal, Dean Bajorin, Nazli Dizman, et al.
JCO Precision Oncology|June 21, 2019
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate TumorsJon H Chung, Ninad Dewal, Ethan Sokol, et al.
Lancet (London, England)|February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialSumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
The Oncologist|December 17, 2015
Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic AlterationsSiraj M Ali, Sumanta K Pal, Kai Wang, et al.
Cancer|December 21, 2018
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesPetros Grivas, Amir Mortazavi, Joel Picus, et al.
Pageof 154